Onychomycosis - Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therap - openPR

Onychomycosis Pipeline Insight

Onychomycosis Pipeline Insight

As per Global Insight services' assessment, about 13 prominent pharma and biotech giants are working on 13 drugs in the Onychomycosis - pipeline landscape globally. Onychomycosis Pipeline Insight, 2023" report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.

Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies: https://www.globalinsightservices.com/request-sample/GIS31243


Onychomycosis is a fungal infection of the nail plate, nail bed, or both. Infection may be distal subungual, with nail thickening and yellowing and accumulation of keratin and debris underneath the nail, proximal subungual or white superficial with spreading of chalky white scale beneath the nail surface.

Onychomycosis is caused by 3 main classes of fungi: dermatophytes, yeasts, and non-dermatophyte molds. Dermatophytes are by far the most common cause of onychomycosis. Onychomycosis can cause pain, discomfort, and disfigurement. Onychomycosis is highly prevalent, particularly among older men and patients with compromised distal circulation, nail dystrophies, and/or tinea pedis.

Read more about Onychomycosis Pipeline Insight here: https://www.globalinsightservices.com/reports/onychomycosis-drug-pipeline-landscape/

Report Highlights:

Global Insight Service's, Onychomycosis - Drug Pipeline Landscape, 2023 report provides an overview of the Onychomycosis pipeline drugs. This report covers detailed insights on Onychomycosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Onychomycosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology:

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope:

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Onychomycosis treatment such as Efinaconazole, MOB015, BB2603 and others. Key players involved in the development of therapies to treat Onychomycosis are Almirall, AmtixBio Co Ltd, Blueberry Therapeutics, Moberg Pharma AB, NovaBiotics and others. Two drugs are under late-stage pre-registration, seven drugs are in Phase II clinical trials and two drugs are in Phase I clinical trials and some other drugs are under preclinical stages of development.

For In-Depth Competitive Analysis, Purchase this Report: https://www.globalinsightservices.com/checkout/single_user/GIS31243

Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like:

- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.

Comments

Post a Comment

Popular posts from this blog

Roseola vs. measles rash: What is the difference? - Medical News Today

Image
Roseola and measles are two different diseases that present with a high fever and a rash. They are both most commonly seen in childhood, although measles can affect people of any age, and roseola in adults is very rare. While both diseases share similarities, there are distinguishing factors, such as how the symptoms present and the disease progression. Read on to find out the difference between roseola and measles rashes. Roseola, also known as roseola infantum, sixth disease, or exanthema subitum, is a viral infection that typically affects children. The human herpesvirus 6 (HHV-6) or human herpesvirus 7 (HHV-7) causes roseola. The disease is spread through tiny respiratory droplets that people either breathe in or pick up from surfaces they touch. This disease usually presents in children between the ages of 6–12 months . Children who have this disease experience a high fever, followed by a pink or red rash. Roseola is a self-limiting viral illness, meaning it will typically go awa...
Read more

poliomyelitis treatment

Image
poliomyelitis treatment Drug and Device News March 2019 - P&T Community Posted: 04 Mar 2019 10:35 AM PST NEW DRUG APPROVALS Ontruzant, a Herceptin Biosimilar The FDA has approved trastuzumabdttb (Ontruzant, Samsung Bioepis Company, Ltd.) for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Trastuzumabdttb, a HER2/neu receptor antagonist, is the third FDA-approved biosimilar of Herceptin (Genentech). Patients should be selected for therapy based on an FDA-approved companion diagnostic. Trastuzumab-dttb carries a boxed warning about the risks of cardiomyopathy, serious and fatal infusion reactions, embryo-fetal toxicity, and pulmonary toxicity. Ontruzant will be marketed and distributed in the U.S. by Merck. Sources: Samsung Bioepis, January 21, 2019; Ontruzant . prescribing information, January 2019; FDA, January 18, 2019 Vaxelis, a Combination Vaccine T...
Read more

Coronavirus fake news echoes century-old polio fears - Newsroom

Image
Coronavirus fake news echoes century-old polio fears - Newsroom Coronavirus fake news echoes century-old polio fears - Newsroom Posted: 05 Feb 2020 08:32 AM PST FEBRUARY 6, 2020 Updated 15 hours ago Dr Heather Battles Dr Heather Battles is a lecturer in anthropology at the University of Auckland and researches infectious diseases and epidemics. Show more Ideasroom During the past month, in the confusion and uncertainty over the precise origin of the 2019 novel coronavirus outbreak, many alternate ideas or 'conspiracy theories' have sprung up and spread widely via social media including Twitter and Facebook. I have had a sense of déjà vu as many of these claims have parallels in how people responded to another 'emerging' epidemic disease a century ago: polio. The first example that struck me is the idea (spread by US fake news website Infowars and others) that the roll-out of 5G technology is to blame, wit...
Read more